XML 50 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Commercial Services and Loan Agreements with Eversana - Additional Information (Detail) - USD ($)
12 Months Ended
Feb. 01, 2022
Jan. 21, 2020
Dec. 31, 2022
Dec. 31, 2021
Jan. 31, 2020
Commercial Services And Loan Agreements [Line Items]          
Selling, general and administrative     $ 9,623,599 $ 8,851,129  
Eversana Agreement [Member]          
Commercial Services And Loan Agreements [Line Items]          
Unreimbursed commercialization cost     $ 48,400,000    
Agreement term     On February 1, 2022, the Eversana Agreement was amended to extend the term from June 19, 2025 (five years from the date the Food & Drug Administration approved the Gimoti new drug application) to December 31, 2026, unless terminated earlier pursuant to its terms.    
Agreement expiration date Dec. 31, 2026        
Selling, general and administrative     $ 2,000,000.0 $ 1,300,000  
Eversana Agreement [Member] | Revolving Credit Facility [Member]          
Commercial Services And Loan Agreements [Line Items]          
Line of credit   $ 5,000,000      
Line of credit facility, Interest rate   10.00%      
Borrowings         $ 5,000,000
Eversana Agreement [Member] | Gimoti [Member] | Minimum [Member]          
Commercial Services And Loan Agreements [Line Items]          
Percentage of Product Profits   80.00%